Baxter has announced plans to buy gene therapy developer Chatham Therapeutics for $70m in a deal focused on the latter’s pipeline of haemophilia candidates and gene therapy delivery platform.
Lonza is targeting the gene therapy sector through a new partnership with Avalanche Biotechnologies that will seek to outlicense viral vector tech and process development knowhow.
Gene therapy could be advanced by a worm more commonly associated with causing a deadly parasitic disease, according to researchers presenting at the British Pharmaceutical Conference (BPC).
At a packed out session at last week's Controlled Release Society
meeting in the US, two experts battled it out to win one of the key
debates in gene delivery: which is superior - viral or non-viral
delivery?
Genzyme has put pen to paper on a licensing deal for Ceregene's
Parkinson's drug, as a rival gene therapy for the same disease
shows promise in initial clinical trials.
A French firm developing an innovative gene delivery tool has
received a cash boost of €80,000 to ramp up good manufacturing
processes for its synthetic delivery molecule.
Viral vector manufacturer Lentigen has entered into a collaboration
with Wave Biotech to gain access to disposable process and
equipment expertise, which ties in with a shift in the bioprocess
manufacturing sector towards using disposable...
With two acquisitions in two months, US biotechnology major Genzyme
has strengthened and diversified its ability to develop gene
therapy products that use either adenovirus or adeno-associated
virus vectors.
Increasing knowledge about how to manage the risks of gene therapy
is set to usher in a new era in disease therapies, with the
prospect of developing treatments in treating rare, inherited, or
life-threatening diseases very real.
A new technique that adds to the effectiveness of gene therapy has
made a breakthrough after it was revealed that the method had cured
phenylketonuria (PKU) in mice.
Researchers in the US have constructed a new virus-based gene
therapy delivery system that has uses in cancer treatment. The
findings are said to provide a solution to the problems that have
hampered gene therapy treatments.
Researchers have achieved the first ever gene therapy success for
muscular dystrophy using a new systemic approach, which
demonstrated that the scientific challenges that have cast doubt on
gene therapy ever being feasible for children...
New analysis into the gene therapy market reveals that
toxicological complications and poor therapy efficacy have hampered
the growth of this sector in which new ways must be found to
improve clinical efficiency and generate revenue.
The first genetic disease that affects the central nervous system
has been successfully treated in an animal model, which if
successfully applied to humans, could treat an entire class of
diseases called lysosomal storage disorders....
Researchers in the US have shown that nanoparticles can be used to
deliver genetic material into cells safely and effectively,
potentially overcoming the primary obstacle to the development of
gene therapy.
The first grants given in the UK for drug development in early
phase clinical experiments have been awarded to gene therapy trials
that may herald a breakthrough in intra-abdominal cancer which has
an average survival rate of less...
US researchers have found a delivery method for gene therapy that
reaches all the voluntary muscles of a mouse - including heart,
diaphragm and limbs - and reverses the process of muscle-wasting
found in muscular dystrophy.
Growing knowledge about how to manage the risks of gene therapy
could improve the chances of developing successful treatments, said
experts meeting last week to weigh up the progress made on the
technology to date.
Researchers have established the cause of the leukaemia which
developed in two young patients taking part in a pioneering gene
therapy trial to treat the fatal 'baby-in-a-bubble' syndrome.
